泰索帝每周方案治疗晚期乳腺癌及非小细胞肺癌临床疗效观察

目的 :观察泰索帝 (Taxotere)每周用药方案治疗晚期乳腺癌及非小细胞肺癌的临床疗效和毒性反应。方法 :泰索帝 2 5mg m2 ,d1、d8、d15,静脉滴入 1h ,每次给药前 30min予地塞米松 10mg静脉推注。乳腺癌联合吡喃阿霉素 4 0mg m2 ,d2 ,静脉推注 ;非小细胞肺癌联合卡铂 30 0mg m2 ,d2 ,静脉滴入。2 8d为 1个周期。治疗 2个周期。结果 :乳腺癌 5例 ,PR 2例 ,NC 3例 ,有效率 4 0 .0 % ;非小细胞肺癌11例 ,CR 1例 ,PR 3例 ,NC 5例 ,PD 2例 ,有效率 36 4 %。全组 16例 ,有效 6例 ,总有效率 37 5 %。毒性反应主要为白细胞减少 ,但无Ⅳ度者。非血液毒性为乏力、恶心及脱发。结论 :泰索帝每周给药方案与每 3周给药方案相比疗效基本相同且具有良好的耐受性 ,骨髓抑制轻微

Clinical Observation on Taxotere Administered by Three Consecutive Weekly Infusions in the Treatment of Advanced Breast Cancer and NSCLC

Objective To observe the response and toxic reaction of Taxotere administered by three consecutive weekly infusions in the treatment of advanced breast cancer and NSCLC.Methods All patients received Taxotere 25mg/m 2 on days 1,8,15 every 4 weeks,intravenous infusion for 1 hour,and 10mg doses of dexamethasone was administered by infusion before the Taxotere infusion.For breast cancer,the Taxotere was combined with THP-ADM 40mg/m 2;for NSCLC ,the Taxotere was combined with CBP 300 mg/m 2.At least 2 cycles were given.Results In 5 breast cancer patients,there were 2 PR,3 NC.In 11 NSCLC patients,there were 1 CR,3 PR,5 NC and 2 PD.Of 16 patients,overall response rate was 37.5%.The major toxic reaction was neutropenia, but grade 4 neutropenia didn't occur. Nonhematologic toxicities included fatigue?nausea and alopecia.Conclusion Weekly administration of Taxotere is well tolerated and produces substantially less mylesuppression than that is observed with standard Taxotere administration every 3 weeks,and also appears to be an effective schedule.